drugset / Trial / NCT02004041

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

NCT02004041

Phase 2 Completed 69 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.

Timeline

Start
2013-12-10
Primary completion
2015-02-19
Completion
2015-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule

Indications